This page is intended to provide scientific information to scientific research professionals. Gossamer Bio’s drug candidates are investigational medicines and have not been approved by The United States Food and Drug Administration (USFDA), Health Canada, the European Medicines Agency (EMA), nor any other regulatory agency.
Publications
Seralutinib for the Treatment of Pulmonary Arterial Hypertension (PAH): Results from the Phase 2 TORREY Trial
PHPN - Sept 2023
Effects of Inhaled Seralutinib on Right Ventricular-Pulmonary Arterial (RV-PA) Coupling and Right Heart Function in Pulmonary Arterial Hypertension (PAH)
PHPN - Sept 2023
See More
Scientific Congresses
Seralutinib improves pulmonary arterial blood vessel volume distribution in pulmonary arterial hypertension (PAH): Results of the TORREY Phase 2 imaging substudy
ERS – September 2023
Effects of Inhaled Seralutinib on Right Ventricular Pulmonary Arterial Coupling and Right Heart Function in Pulmonary Arterial Hypertension
ESC – August 2023
Seralutinib Improves Pulmonary Arterial Blood Vessel Volume Distribution in Pulmonary Arterial Hypertension (PAH): Results of the TORREY Phase 2 Imaging Substudy
ERS - September 2023
See More
Seralutinib MOA Video
A targeted approach to the proliferation, fibrosis, and inflammation associated with Pulmonary Arterial Hypertension
Targeting the underlying mechanisms of Pulmonary Arterial Hypertension